AMTI Applied Molecular Transport Inc.

FDA Catalyst Company
4.26
+0.27  (+7%)
Previous Close 3.99
Open 4.09
52 Week Low 3.41
52 Week High 52.71
Market Cap $164,666,734
Shares 38,654,163
Float 13,010,765
Enterprise Value $37,660,985
Volume 94,343
Av. Daily Volume 348,892
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/10/2022
JMP Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/17/2021
SVB Leerink Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/22/2021

Latest News

  1. Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis

    • Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3

    Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance

    SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

    "We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pouchitis patients, the first of four important AMT-101…

    View Full Article
  2. SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the BofA Securities 2022 Healthcare Conference in Las Vegas on Tuesday, May 10, 2022 at 2:20 p.m. ET (11:20 a.m. PT).

    A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.

    About Applied Molecular Transport Inc.

    AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product…

    View Full Article
  3. –  Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)
    –  AMT-101 demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile
    –  
    Achieved clinically meaningful responses in stool frequency and histologic healing in both 3mg and 10mg dosage groups
    –  
    Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 in chronic pouchitis
    –  
    Further substantiates potential of AMT-101 and Company's oral biologics platform
    –  
    Investor conference call and webcast today at 8:30 a.m. ET (5:30 a.m. PT)

    SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today…

    View Full Article
  4. - Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT)

    SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 FILLMORE monotherapy trial for AMT-101 (GI- selective, oral fusion of IL-10) in patients with chronic pouchitis in a premarket press release and webcasted conference call on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT).

    Conference Call & Webcast Information
    To participate in the conference call, please dial (844) 422-9742 (Domestic) or (706) 758-6032 (International) and refer to conference ID 5649019. The live webcast will be accessible…

    View Full Article
  5. Publication describes critical interactions between cholix-based transport domain and endogenous intracellular trafficking pathways used by Company's proprietary biologic product candidates to cross intestinal epithelial barrier

    Deep characterization of natural molecular trafficking mechanisms provides novel pathway biology insights, furthers Company's technology platform to address a wider range of disease targets and strengthens wholly-owned IP portfolio

    SOUTH SAN FRANCISCO, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that new insights into the unique mechanism of action utilized by its oral biologic product candidates, including…

    View Full Article
View All Applied Molecular Transport Inc. News